Clinical trials: Sickle Cell Disorder
Anemia, Sickle Cell
Dipyridamole/Magnesium To Improve Sickle Cell Hydration
The purpose of this study is to determine the benefits as well as side effects of giving drugs called dipyridamole and magnesium to patients with sickle cell anemia (SCA).
- Trial name
- NCT00276146
- Testing
- oral dipyridamole, oral magnesium, or a combination of both
- Where
- 3 sites in United States
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Child, Only, Brain Diseases
Metabolic and Hemodynamic Reserve in Pediatric SCA
The purpose of this research study is to better understand how blood flow and metabolism change can influence brain development in the early decades of life.
- Conditions
- Child, Only, Brain Diseases, Sickle Cell Disease, Anemia, Sickle Cell
- Trial name
- NCT04406818
- Testing
- Carbon Dioxide
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Sickle Cell Disease
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
The goal of this clinical research study is to find out about the safety and effects of a drug called panobinostat when given to adults with sickle cell disease. Panobinostat is a pan histone deacetylase (HDAC) inhibitor.
- Trial name
- LBH589 (NCT01245179)
- Testing
- panobinostat
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Abdullah Kutlar
Sickle Cell Disease, Diabetes Mellitus
Glucose Metabolism in Sickle Cell Disease
The purpose of the study is to better understand how the body handles sugars glucose and fats, such as cholesterol and triglycerides in sickle cell disease, and what puts certain persons at risk to develop diabetes.
- Trial name
- NCT02922296
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- University of Illinois Chicago
Anemia, Sickle Cell, Pneumonia
Arginine Treatment of Acute Chest Syndrome (Pneumonia) in Sickle Cell Disease Patients
This is a study to determine if oral arginine will increase nitric oxide in sickle cell disease (SCD) patients with acute chest syndrome (ACS).
- Trial name
- NCT00029731
- Testing
- Arginine hydrochloride
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- UCSF Benioff Children's Hospital Oakland
Sickle Cell Disease
Pathophysiology of Acute Pain in Patients With Sickle Cell Disease
Background: Sickle Cell Disease (SCD) is a blood disorder that occurs mainly in people of African descent. Researchers want to learn more about the painful attacks and complications associated with SCD.
- Trial name
- NCT03049475
- Where
- United States
- Volunteers
- 99 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Sickle Cell Disease, Sickle Cell Crisis
A Comprehensive Care Plan for Pediatric Patients With Vaso-Occlusive Crises
Sickle cell disease (SCD) is the most common inherited blood disorder affecting 80,000 to 90,000 individuals in the United States.[10] There are 13,000 hospital admissions for a sickle cell crises, costing $448 million dollars…
- Conditions
- Sickle Cell Disease, Sickle Cell Crisis, Vaso-Occlusive Crises
- Trial name
- NCT02698761
- Testing
- Comprehensive Care Plan
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- Valley Anesthesiology Consultants
Sickle Cell Disease
A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD)
This is an open-label, multicenter, within-participant dose-escalation study examining up to 3 dose levels of DISC-3405 and will assess the safety, tolerability, PK, and PD of DISC 3405 in participants with sickle cell disease.
- Trial name
- NCT07187973
- Testing
- DISC-3405
- Where
- 11 sites in United States
- Volunteers
- 24 people
- Sponsor
- Disc Medicine, Inc
Sickle Cell Disease
Pain Management in Children and Young Adults With Sickle Cell Disease
This is a phase II double-blind placebo-controlled clinical trial evaluating the effect of gabapentin when added to standard pain management for patients with sickle cell disease experiencing acute pain crisis in the ambulatory…
- Trial name
- NCT01954927
- Testing
- Gabapentin
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- St. Jude Children's Research Hospital
Sickle Cell Disease, Hb-SS Disease With Vasoocclusive Pain
Abciximab (ReoPro) as a Therapeutic Intervention for Sickle Cell Vaso-Occlusive Pain Crisis
The purpose of this study is to determine whether giving abciximab (ReoPro) to children with sickle cell disease who are hospitalized for acute pain crisis will improve their pain and shorten the time spent in the hospital, when…
- Conditions
- Sickle Cell Disease, Hb-SS Disease With Vasoocclusive Pain, Hemoglobin SS Disease With Vasoocclusive Crisis, Other Sickle Cell Disease With Vaso-Occlusive Pain
- Trial name
- NCT01932554
- Testing
- Abciximab, Intravenous hydration, Ibuprofen
- Where
- United States
- Sponsor
- St. Louis University
Sickle Cell Disease
High-flow Oxygen for Vaso-occlusive Pain Crisis
Sickle cell disease (SCD) is characterized by recurrent vaso-occlusive pain crisis (VOC), which may evolve to acute chest syndrome (ACS), the most common cause of death among adult patients with SCD.
- Trial name
- OSONE (NCT03976180)
- Testing
- Stadard low-flow oxygen, HFNO with low FiO2 (21%-30%), HFNO with intermediate FiO2 (50%)
- Where
- France
- Volunteers
- 350 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Sickle Cell Disease, Thalassemia
Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-thalassemia in People With Higher Risk of Transplant Failure
Background: Some sickle cell disease or beta-thalassemia can be cured with transplant. Researchers want to test a variation of transplant that uses low dose radiation and a combination of immunosuppressive drugs.
- Conditions
- Sickle Cell Disease, Thalassemia, Stem Cell Transplantation, Graft vs Host Disease
- Trial name
- NCT02105766
- Testing
- Alemtuzumab, Sirolimus, Cyclophosphamide
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Sickle Cell Disease
Imatinib for Pain in Sickle Cell Anemia
In this protocol, the investigators propose to evaluate the biochemical effects of imatinib on sickle red blood cells (RBCs). Patients will be administered imatinib mesylate orally following the guidelines previously established…
- Trial name
- IMPACT (NCT03997903)
- Testing
- Imatinib Mesylate
- Where
- 2 sites in United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Indiana University
Hemochromatosis, Cerebrovascular Accident
Stroke With Transfusions Changing to Hydroxyurea
The purpose of this study is to compare standard therapy (transfusions and chelation) with alternative therapy (hydroxyurea and phlebotomy) for the prevention of secondary stroke and management of iron overload in children with…
- Conditions
- Hemochromatosis, Cerebrovascular Accident, Anemia, Sickle Cell, Hematologic Diseases
- Trial name
- NCT00122980
- Testing
- Red Cell Transfusions, Iron Chelation, Hydroxyurea
- Where
- 28 sites in United States
- Volunteers
- 134 people
- Sponsor
- St. Jude Children's Research Hospital
Sickle Cell Disease
Utilizing A Single Session Problem-Solving Intervention With Caregivers of Pediatric Patients Receiving Chronic Transfusion to Treat Sickle Cell Disease
This study seeks to utilize an innovative approach of a single session problem-solving intervention to address psychosocial factors affecting patient outcomes within the pediatric sickle cell population.
- Trial name
- NCT04606160
- Testing
- Single Session Problem-Solving Intervention
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Sickle Cell Disease
A New Reagent Assay Examining Natural Parvovirus B19 Infection in Sickle Cell Disease
Parvovirus B19 is a small virus that is the cause of "fifth" disease, a common infection in childhood. In people with sickle cell disease (SCD), parvovirus B19 infection causes the bone marrow to stop producing red blood cells…
- Trial name
- NCT02261480
- Testing
- Blood draw, Nasopharyngeal wash
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- St. Jude Children's Research Hospital
Sickle Cell Disease, Sickle B+ Thalassemia
The Longitudinal Relationship of HU Adherence to HRQOL, Barriers to Adherence and Habit in SCD.
The primary objective of this study is to better understand factors contributing to variations in hydroxyurea (HU) adherence behavior in adolescents and young adults (AYA) with sickle cell disease (SCD).
- Conditions
- Sickle Cell Disease, Sickle B+ Thalassemia, Sickle Beta Zero Thalassemia, Sickle Cell Hemoglobin C
- Trial name
- NCT04691323
- Testing
- HU-Go app
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
Sickle Cell Disease
Study of Biological Markers in Children With Sickle Cell Disease
Sickle cell disease is associated with significant morbi-mortality hence the interest in an early and targeted care. At present, there is no plasmatic marker able to identify infants at higher risk of developping severe…
- Trial name
- NCT04839159
- Testing
- Blood sampling
- Where
- 3 sites in Belgium
- Volunteers
- 41 people
- Sponsor
- Queen Fabiola Children's University Hospital
Anemia, Sickle Cell
Long-Term Effects of Hydroxyurea in Children With Sickle Cell Anemia (The BABY HUG Follow-up Study)
Sickle cell anemia (SCA) is an inherited blood disorder that can cause organ damage. The BABY HUG study is evaluating the use of the medication hydroxyurea at preventing organ damage in children with SCA.
- Trial name
- NCT00890396
- Testing
- Hydroxyurea
- Where
- 14 sites in United States
- Volunteers
- 163 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Sickle Cell Disease
A Single-Dose Relative Bioavailability Study Of GBT440 300 mg Capsules in Healthy Subjects
The purpose of this study is to evaluate the relative bioavailability of a single 300 mg dose of GBT440 administered as a high strength (1 × 300 mg) capsule versus a low strength (3 × 100 mg) capsule formulation in healthy fasted…
- Trial name
- NCT02567695
- Testing
- GBT440
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Global Blood Therapeutics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.